New drug combo aims to protect kidney transplants from early failure

NCT ID NCT06855758

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether adding terlipressin to standard care helps maintain stable blood pressure during kidney transplant surgery. Researchers will compare two groups of 150 adults: one receiving terlipressin plus dobutamine, the other dobutamine alone. The main goal is to see if terlipressin reduces the need for dialysis in the first week after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
terlipressin
What this could lead to
If it works, this could improve blood pressure control during kidney transplant surgery and reduce the need for dialysis shortly after transplant.
What could go wrong
This is a small, early-stage trial (150 people) testing a drug already used for other conditions. The benefit may be modest or not confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DELAYED GRAFT FUNCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Delayed Graft Function end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Friendship Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.